Current Lab Members
Research Assistant Professor
Dmitri is working on single-cell sequencing of patient-derived tumor cells to understand how breast cancer heterogeneity plays a role in the metastatic potential and drug resistance. In addition, working on a project to identify tumor-specific T cell receptor sequences in order to design means for earlier detection of breast cancer.
Senior Research Associate
Myron works on construction and maintenance of pipelines specific to mutation calling.
Pavana works on pipelines related to analysis of TCGA and ICGC data.
Kami is a Bioinformatics Research Associate primarily focused on customization and implementation of algorithms for analysis of multidimensional "omics" data. With a particular interest in transcriptomics, she works to identify tumor-specific gene targets for immunologic and/or pharmacologic therapies. She also assists with development and containerization of computational pipelines designed for high-throughput DNA or RNA sequence analysis of a variety of features, such as mutation timing, copy number variants, structural aberrations, cluster analysis, and alternative splicing events.
Lab Manager, Senior Research Assistant, Next Generation Sequencing Specialist
Chris has been with Dr. Paul Spellman's research laboratory at OHSU since 2013 and formally managed the lab since 2015. He specializes in the identification of tumor-derived mutations in blood samples using next-generation sequencing of cell free DNA. He has developed custom error-correction techniques that enable the accurate detection of known and de novo mutations present in only one in 10,000-100,000 molecules (0.01%-0.001% variant allele frequency). These methods to detect rare variants in blood from cancer patients provide a promising means for the early detection of recurrence as well as the identification of genetic alterations derived from metastases invisible to standard imaging technologies. The longitudinal study of cell free DNA may provide many other valuable insights into the course of a patient's disease as well. Chris currently works on research projects that use his methods to understand the clonal dynamics of tumor evolution, predict responses to therapy, and uncover genetic mechanisms of therapeutic resistance.
Asia studies clear-cell renal cell carcinomas from individuals with VHL syndrome. In performing whole-genome and exome sequencing across more than 150 synchronous renal carcinomas, our lab has identified several observations providing insight into tumor evolution (Fei et al. Nature Communications, 2016). Above all, our work demonstrates that synchronous renal carcinomas (From VHL Syndrome patients) are an under-utilized and promising biological system for probing tumor evolution.